Clinical trial
Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in…
NCT00064714 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00064714 |
|---|---|
| Title | Effect of AC2993 With or Without Immunosuppression on Beta Cell Function in Patients With Type I Diabetes |
| Official title | Effect of AC 2993 (Synthetic Exendin-4) - Administered Alone or in Combination With Daclizumab - on Islet Function in Patients With Type I Diabetes |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | AC2993 (exenatide), daclizumab (immunosuppressive) |
| Enrollment | 47 |
| Start date | Jul 1, 2003 |
| Primary completion | Mar 1, 2008 |
| Completion | Mar 1, 2008 |
| First posted | Jul 11, 2003 |
| Last update posted | Mar 11, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: